South San Francisco, CA, November 6, 2024 – FlemingMartin is pleased to announce that Alumis, a clinical-stage biopharmaceutical company developing novel oral therapies to treat immune-mediated diseases, has hired Dr. Rajesh “Raj” Punwaney as Vice President of Clinical Development – Rheumatology.
Raj is a clinical development leader with more than 20 years of industry experience from companies such as GSK, Galvani Bioelectronics, and Roivant Sciences. Raj holds a significant background in R&D asset development, having driven programs across numerous rheumatologic and immunologic indications over his career (including systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, IBD, and CIDP). Raj prides himself on a robust ability to guide global teams while cultivating strong relationships with investigators, physicians, investors, scientists, boards, KOLs, patient advocacy groups, and other key stakeholders. Raj earned his MD from Mount Sinai School of Medicine, received his MBA in Healthcare from City University of New York – Baruch College, and graduated with a BA in Economics and Pre-Medicine from Columbia University. He also currently serves on the Board of Directors for Evaeon Life Technology.
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies.
